Mizuho Hanaki

Structural insights into mechanisms for inhibiting amyloid β42 aggregation by non-catechol-type flavonoids

Mizuho Hanaki, Kazuma Murakami, Ken‐ichi Akagi et al. · Bioorganic & Medicinal Chemistry · 2015 · 60 citations · Full text

Polyphenolics, Biochemistry, Non-catechol-type Flavonoids +4

Monoclonal antibody with conformational specificity for a toxic conformer of amyloid β42 and its application toward the Alzheimer’s disease diagnosis

Kazuma Murakami, Maki Tokuda, Takashi Suzuki et al. · Scientific Reports · 2016 · 58 citations · Full text

Inhibitory Activities of Antioxidant Flavonoids from <i>Tamarix gallica</i> on Amyloid Aggregation Related to Alzheimer’s and Type 2 Diabetes Diseases

Asma Ben Hmidene, Mizuho Hanaki, Kazuma Murakami et al. · Biological and Pharmaceutical Bulletin · 2017 · 49 citations · Full text

Neurodegenerative Diseases, Medicinal Chemistry, Alzheimer's Disease +15

Semisynthesis and Structure–Activity Studies of Uncarinic Acid C Isolated from <i>Uncaria rhynchophylla</i> as a Specific Inhibitor of the Nucleation Phase in Amyloid β42 Aggregation

Takuya Yoshioka, Kazuma Murakami, Kyohei Ido et al. · Journal of Natural Products · 2016 · 33 citations

Role of the carboxy groups of triterpenoids in their inhibition of the nucleation of amyloid β42 required for forming toxic oligomers

Kazuma Murakami, Takuya Yoshioka, Shiori Horii et al. · Chemical Communications · 2018 · 32 citations